Title:A Data Resource for Analyzing Blood and Marrow Transplants (Limited Competition U24)

Contact:

Dr. Roy S. Wu
Clinical Grants and Contracts Branch
Clinical Therapy Evaluation Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
6130 Executive Boulevard, EPN Room 7009, MSC 7432
Bethesda, MD 20892-7432 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for express/courier delivery; non-USPS service)
Telephone: 301-496-8866
Fax: 301-480-4663
E-mail: wur@ctep.nci.nih.gov

Dr. Nancy DiFronzo
Transfusion Medicine and Cellular Therapeutics Branch
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Room 10146, MSC 7950
Bethesda, MD 20892-7950
Telephone: 301-435-0065
Fax: 301-480-1046
E-mail: difronzon@nhlbi.nih.gov

Dr. Linda M. Griffith
Division of Allergy, Immunology, and Transplantation
National Institute of Allergy and Infectious Diseases
6610 Rockledge Drive, Room 3025, MSC 6601
Bethesda, MD 20892-6601
Telephone: 301-496-7104
Fax: 301-480-1450
E-mail: lgriffith@mail.nih.gov

Objective of Project:

The Funding Opportunity Announcement (FOA) requests the submission of a limited competition renewal application from the Center for International Blood and Marrow Transplant Research (CIBMTR). The CIBMTR serves as a data resource for analyzing blood and marrow transplants and is currently funded as a cooperative agreement (U24). This limited competition RFA is designed to continue the support of CIBMTR as a research quality data resource.

Description of Project:

The CIBMTR database is available to investigators and health policy makers. The CIBMTR collects consecutive transplant outcomes data from transplant centers in the world and includes approximately 60% of transplants done in the United States (U.S.). The CIBMTR database has information for more than 232,000 hematopoietic cell transplant (HCT) recipients (125,000 allogeneic and 107,000 autologous transplants). Approximately 85% of allogeneic and greater than 99% of autologous transplants performed are for treatment of human malignancies. Approximately 50% of the allogeneic data is of research quality with the remaining 50% containing basic information. Approximately 25% percent of the autologous data is of research quality with the remaining 75% containing basic information. More than 450 HCT centers in 47 countries are currently submitting data to the CIBMTR. The CIBMTR has a proven system for facilitating the use of its database for research and a record of collaboration with government agencies, professional groups, international partners, and patient organizations via 18 scientific/research working committees.